ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "PD-1"

  • Abstract Number: 99 • 2019 ACR/ARP Annual Meeting

    Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis

    Runci Wang1, Karmela Kim Chan 2, Amy Cunningham-Bussel 3, Laura Donlin 4, Gregory Vitone 2, Aidan Tirpack 2, Caroline Benson 2, Gregory Keras 3, Anna Helena Jonsson 5, Michael Brenner 6, Anne Bass 7 and Deepak Rao 1, 1Brigham and women's hospital, Boston, MA, 2Hospital For Special Surgery, New York, 3Brigham and women's hospital, Boston, 4Hospital For Special Surgery, New York, NY, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Brigham and Women’s Hospital:, Boston, 7Hospital for Special Surgery/Weill Cornell Medicine, New York, NY

    Background/Purpose: Anti-PD-1/PD-L1 checkpoint inhibitor therapies have produced remarkable results in stimulating immune responses against tumors. Checkpoint inhibitor therapy can also trigger a variety of autoimmune…
  • Abstract Number: 1809 • 2019 ACR/ARP Annual Meeting

    A Quarter of Patients Treated with Checkpoint Inhibitors Develop Immune-Related Adverse Events: A University Center Experience

    Celine Zhou 1, Whitney Elg-Salsman1, Sonam Kiwalkar 2, Nishad Sathe 1, Marcia Friedman 1 and Atul Deodhar 2, 1Oregon Health and Science University, Portland, OR, 2Oregon Health & Science University, Portland, OR

    Background/Purpose: Immune checkpoint inhibitors (ICIs) are increasingly becoming the mainstay of management of advanced malignancies, but can result in immune related adverse events (irAEs) affecting…
  • Abstract Number: 150 • 2018 ACR/ARHP Annual Meeting

    PD-1 Signaling Interferes with OX40L to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice

    Maida Wong1 and Bevra H Hahn2, 1Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA, 2Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: In systemic lupus erythematosus (SLE), the dysregulated production of autoantibodies is a consequence of disrupted T cell homeostasis. Programmed death-1 (PD-1), a negative regulator…
  • Abstract Number: 351 • 2018 ACR/ARHP Annual Meeting

    Rheumatic Immune-Related Adverse Events in Patients on ANTI-PD-1 Inhibitors: Fasciitis with Myositis Syndrome As a New Rheumatic Complication of Immunotherapy

    Francisco Javier Narváez1, Pablo Juárez2, Judit Lluch2, Jose Antonio Narvaez3, Ramón Palmero4, Xavier Garcia del Muro4, Joan Miquel Nolla2 and Eva Domingo-Domenech5, 1Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 2Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Radiology, Hospital Universitari de Bellvitge, Barcelona, Spain, 4Medical Oncology., Institut Català d'Oncologia. Hospital Duran i Reynals., Barcelona, Spain, 5Hematology, Institut Català d'Oncologia. Hospital Duran i Reynals, Barcelona, Spain

    Background/Purpose: To evaluate the prevalence and type of rheumatic immune-related adverse events (IRAEs) in patients receiving programmed cell death protein-1 (PD-1) inhibitors. Methods: This is…
  • Abstract Number: 357 • 2018 ACR/ARHP Annual Meeting

    Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia

    Abhishikta Dey1,2, Nicholas Manolios3,4, Georgina Long4,5,6, Richard Kefford3,4,5,7 and Leslie Schrieber8,9, 1Pain Medicine, Royal Prince Alfred Hospital, Camperdown, Australia, 2Royal North Shore Hospital, North Sydney, Australia, 3Westmead Hospital, Sydney, Australia, 4University of Sydney, Sydney, Australia, 5Melanoma Institute Australia, North Sydney, Australia, 6Royal North Shore Hospital, St Leonards, Australia, 7Macquarie University Hospital, Sydney, Australia, 8Royal North Shore Hospital, St Leonards, Sydney, Australia, 9Northern Clinical School, University of Sydney, Sydney, Australia

    Background/Purpose: The strategy of using monoclonal antibodies to inhibit checkpoints on T cells, and enhance T-cell activity against cancer cells has significantly improved the survival…
  • Abstract Number: 361 • 2018 ACR/ARHP Annual Meeting

    Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab

    In Young Kim1, Yeonghee Eun1, Hyungjin Kim1, Joong Kyong Ahn2, Eun-Jung Park3, Chan Hong Jeon4, Jinseok Kim5, Hoon-Suk Cha1, Eun-Mi Koh1 and Jaejoon Lee1, 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), 2Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), 3Department of Medicine, National Medical Center, Seoul, Korea, Republic of (South), 4Department of Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), 5Department of Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South)

    Background/Purpose: Immune checkpoint inhibitors have been established as a novel standard treatment for various types of malignancies. However, these new class of drugs have led…
  • Abstract Number: 2459 • 2018 ACR/ARHP Annual Meeting

    Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy

    William Murray-Brown1, Helen Weedon1, Tom Wilsdon2, Susanna Proudman3, Jenny Walker1, Malcolm D. Smith4 and Mihir D Wechalekar1,5, 1Rheumatology, Flinders University, Adelaide, Australia, 2Rheumatology, Flinders Medical Centre, Adelaide, Australia, 3Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, 4Rheumotology, Flinders University, Adelaide, Australia, 5Royal Adelaide Hospital, Adelaide, Australia

    Background/Purpose: Checkpoint inhibitors (CI) for cancer therapy are associated with inflammation that can recapitulate features of autoimmunity, including synovitis resembling rheumatoid arthritis (RA). No reports…
  • Abstract Number: 2797 • 2018 ACR/ARHP Annual Meeting

    Regulation of Autoimmune T Cells By the Co-Receptors CD28 and PD-1

    Sabina Sandigursky1 and Adam Mor2, 1Medicine, NYU School of Medicine, New York, NY, 2Rheumatology and Pathology, NYU School of Medicine, New York, NY

    Background/Purpose: T cells play a major role in the pathogenesis of Rheumatoid Arthritis (RA). These cells are regulated by signals provided via the T cell…
  • Abstract Number: 2095 • 2017 ACR/ARHP Annual Meeting

    Traditional Disease Modifying Anti-Rheumatic Drugs (tDMARDs), Hydroxychloroquine (HCQ) and/or Sulfasalazine (SSZ), Are Rapidly Effective in Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis

    Jessie Alperin1, Jeffrey Sarazin2, Leslie Fecher3, Christopher Lao3, Seetha Monrad4, David Fox1 and Elena Schiopu5, 1University of Michigan Medical System, Ann Arbor, MI, 2Rheumatology, University of Michigan Medical System, Ann Arbor, MI, 3Oncology, University of Michigan Medical System, Ann Arbor, MI, 4Internal Medicine/Rheumatology, University of Michigan Medical System, Ann Arbor, MI, 5Internal Medicine, University of Michigan Medical System, Ann Arbor, MI

     Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is widely used in the treatment of metastatic melanoma and non-small cell lung cancer and it is under investigation…
  • Abstract Number: 2580 • 2017 ACR/ARHP Annual Meeting

    Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block

    Robert M. Clancy1, Glenn Fishman1, Colin Phoon1, Marc Halushka2, Tanisha Jackson1, Kimberly Robins1 and Jill P. Buyon1, 1NYU School of Medicine, New York, NY, 2Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: The most serious manifestation of fetal exposure to maternal anti-Ro antibodies is the development of heart block. This work addresses the hypothesis that fetal…
  • Abstract Number: 2705 • 2017 ACR/ARHP Annual Meeting

    Aberrant Expression and Function of Human Circulating T Follicular Helper Cells and Its Subsets in IgG4 Related Disease

    Yu Chen1, Wen Zhang2, Panpan Zhang3, Yanan Zhu1 and Hongxian Yang3, 1Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, 2Rheuamtology, Peking Union Medical College Hospital, Beijing, China, 3rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

    Background/Purpose: To study the expression and function of T follicular helper cells and its subsets in IgG4-related disease(IgG4-RD). Methods: Flow cytometry was performed to analyze…
  • Abstract Number: 1340 • 2016 ACR/ARHP Annual Meeting

    Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution

    Olga Pinkston1, Florentina Berianu1 and Benjamin Wang2, 1Rheumatology, Mayo Clinic, Jacksonville, FL, 2Division of Rheumatology, Mayo Clinic, Jacksonville, FL

    Background/Purpose: Although immune checkpoint inhibitors improve survival in patients with melanoma and other cancers, the alterations to the immune system induced by these medications can…
  • Abstract Number: 2925 • 2016 ACR/ARHP Annual Meeting

    Programmed Cell Death (PD)-1 May Play a Significant Role in the Pathogenesis of Rheumatoid Arthritis

    Sabina Sandigursky1 and Adam Mor2, 1Medicine, NYU, New York, NY, 2Rheumatology and Pathology, NYU Langone Medical Center, New York, NY

    Background/Purpose: PD-1 is a co-inhibitory transmembrane protein with a significant effect on immune regulation. Several studies have shown elevated expression levels of PD-1 on T…
  • Abstract Number: 3042 • 2016 ACR/ARHP Annual Meeting

    PD-1–Expressing T Cells in GCA Fail to Promote Immune Tolerance Functions

    Ryu Watanabe1, Hui Zhang2, Ebru Hosgur2, Gerald Berry3, Jorg Goronzy4 and Cornelia M. Weyand2, 1Medicine: Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA, 2Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 3Pathology, Stanford University School of Medicine, Stanford, CA, 4Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA

    Background/Purpose:  The vasculitic lesions in GCA are filled with differentiated effector T cells that sustain granuloma formation, vessel wall restructuring, neoangiogenesis and intimal hyperplasia. Persistent…
  • Abstract Number: 2529 • 2015 ACR/ARHP Annual Meeting

    Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta

    Gail Deutsch1,2, Megan Yuasa3 and Anne M. Stevens4,5, 1Pathology, Seattle Children's Hospital, Seattle, WA, 2School of Medicine, University of Washington, Seattle, WA, 3Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, 4Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, 5Pediatrics, University of Washington, Seattle, WA

    Background/Purpose:  The increased rates of preeclampsia, preterm birth, and intrauterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.